Major pharmaceutical companies Takeda ($TAK), Astellas ($ALPMY), and Sumitomo Mitsui Banking have entered into a master agreement to form a joint venture focused on incubating early drug discovery programs in Japan. This initiative aims to revitalize the Japanese pharmaceutical research and development sector, which has been losing momentum. The joint venture will leverage advancements in AI and technology to enhance drug design and development processes, as highlighted in recent discussions about the use of AI in creating more effective medicines. Exscientia, an early partner in AI drug design, has already seen success with the first AI-designed drug entering clinical trials ($EXAI).
Pharmas form joint venture to jumpstart Japanese drug research https://t.co/GtjjRVuZTc by @BentheFidler
Exscientia's Ben Taylor talks to the Japanese Nikkei about overcoming design failures in drug discovery with AI. (Japan's Sumitomo Pharma was an early parter of Exscientia's & yielded the first truly AI designed drug to enter the clinic) $EXAI. https://t.co/IVD8K7u2hj
Pharmas form joint venture to jumpstart Japanese drug research https://t.co/1GCIx50T8n $TAK $ALPMY
Congratulations @drrichjlaw @exscientiaAI on this excellent interview with @TrishaGoddard, explaining how #AI & #technology are used to aim for faster #drug design & development of the best-possible #medicines for #patients. Compelling insights! https://t.co/y5S8hizk2V
Interesting answer to the inexorable loss of momentum ofπ―π΅pharma R&D Takeda $TAK, #Astellas and #Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs (R&D originating fromπ―π΅) https://t.co/UoqM6v91LF https://t.co/qcgijbpR1k